VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC)
This observational study will investigate the efficacy and tolerability of Vargatef (Nintedanib) plus docetaxel in daily routine second-line treatment in patients with locally advanced, metastatic or locally recurrent NSCLC. Treatment with Vargatef in eligible NSCLC patients, for whom the treating physician has decided to initiate treatment with Vargatef in second line according to the local label, will be observed for up to 24 months. Survial follow-up will be done until the end of the study.
Carcinoma, Non-Small-Cell Lung
DRUG: treatment
Percentage of patients alive one year after start of therapy with Vargatef and Docetaxel (1-year survival rate), up to 24 months
One year survival rate of patients with first line progression within 9 months after start of first line therapy, up to 24 months|Progression-free survival of patients with first line progression within 9 months after start of first line therapy, up to 24 months|Median overall survival, up to 24 months|Progression-free survival, up to 24 months|Tumour control rate (complete response, partial response, stable disease), up to 24 months|Incidence of side effects, up to 24 months
This observational study will investigate the efficacy and tolerability of Vargatef (Nintedanib) plus docetaxel in daily routine second-line treatment in patients with locally advanced, metastatic or locally recurrent NSCLC. Treatment with Vargatef in eligible NSCLC patients, for whom the treating physician has decided to initiate treatment with Vargatef in second line according to the local label, will be observed for up to 24 months. Survial follow-up will be done until the end of the study.